PLANTATION, Fla., April 25 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) and its majority-owned subsidiary, Viragen International, Inc.
(OTC Bulletin Board: VGNI), today announced the approval of Multiferon(R),
natural human alpha interferon, for sale in the Philippines.
Multiferon(R) was approved in the Philippines for the second-line
treatment of any and all diseases in which recombinant interferon therapy
failed or the patient was unable to tolerate the regimen. As an alternative
to single-subtype, recombinant alpha interferons, Multiferon(R) is primarily
marketed for the treatment of hepatitis B, hepatitis C, chronic myelogenous
leukemia, hairy cell leukemia, renal cell carcinoma and malignant melanoma.
Viragen's President and CEO, Mr. Charles A. Rice, commented, "One of our
stated priority goals for 2005 is to initiate sales of Multiferon(R) in new
markets, and we are pending approvals in parts of Europe, South America and
Asia. The Philippines adds value as part of this international expansion and
is expected to contribute to sales growth as we continue to strive to make
Multiferon(R) the most widely prescribed natural interferon in the world."
About Viragen, Inc.:
Viragen researches, develops and commercializes natural and recombinant
pharmaceutical products designed to treat a broad range of viral and malignant
diseases. These protein-based drugs include: Multiferon(R), a natural human
alpha interferon, approved for sale in various international markets; anti-
cancer monoclonal antibodies; and anti-cancer peptides. Viragen is also
pioneering Avian Transgenic Technology, with the renowned Roslin Institute, as
a biomanufacturing platform for the large-scale, efficient and economical
production of therapeutic proteins.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
